Results 141 to 150 of about 57,442 (306)

Effect of enzalutamide on anticoagulant therapy with edoxaban in patients with prostate cancer

British Journal of Clinical Pharmacology, EarlyView.
Aims Treatment with enzalutamide in prostate cancer is challenging due to its high potential for drug–drug interactions, particularly in the typically older population of patients with frequent comorbidities treated with multiple drugs, such as anticoagulants.
Catharina J. P. Op 't Hoog, Niven Mehra, Anouk van Kleef, Diederik M. Somford, Inge M. van Oort, Alex L. T. Imholz, Paul Hamberg, Nielka P. van Erp, Emmy Boerrigter   +8 more
wiley   +1 more source

AN EARLY SARMATIAN BURIAL FROM KURGAN 3 OF THE CHEBOTAREVO IV KURGAN CEMETERY

Нижневолжский археологический вестник
This study introduces into scholarly circulation materials from an undisturbed elite Early Sarmatian burial in kurgan 3 of the Chebotarevo IV kurgan cemetery on the right bank of the Ural River.
Sergey Zakharov, Denis Maryksin
doaj   +1 more source

Effects of Renal and Hepatic Impairment on the Pharmacokinetics of Zilurgisertib

British Journal of Clinical Pharmacology, EarlyView.
Aim Small‐molecule activin receptor‐like kinase‐2 inhibitor zilurgisertib (INCB000928) is under investigation in a pivotal trial for the treatment of fibrodysplasia ossificans progressiva (FOP), an ultrarare genetic condition. This analysis assessed effects of renal and hepatic impairment on zilurgisertib pharmacokinetics.
Yan‐ou Yang, Yunlan Fang, Phillip Wang, Xiang Liu, Jay Getsy, Kevin Rockich   +5 more
wiley   +1 more source

An open‐label, single‐arm, dose‐escalating concentration–QT study to investigate the cardiac effects and safety of paroxetine in healthy adults

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Paroxetine is a selective serotonin reuptake inhibitor (SSRI), approved for treatment of major depressive disorder and anxiety disorders. Some SSRIs are known to prolong the QT interval; however, clinical evidence to establish a lack of association between paroxetine and corrected QT interval (QTc) prolongation is limited. Therefore, this
Sven C. van Dijkman, Mathieu Félices, Bhaskar Pandurangavittal, Sanman Ghorpade, Caroline Easterbrook, Marcin Zabielski, Oscar Della Pasqua   +6 more
wiley   +1 more source

Prescribing variation across Europe: Insights into prescribing practices and educational needs

British Journal of Clinical Pharmacology, EarlyView.
Aims Prescribing medication is a complex process, influenced by many factors that can be weighed differently. Four prescriber profiles have been identified: pragmatic‐contextual, guideline‐oriented, experience‐driven and vulnerability‐focused. However, the extent to which European prescribers identify with these profiles and the role of these profiles ...
Mariëlle G. Hartjes, Milan C. Richir, Michiel A. van Agtmael, Jelle Tichelaar   +3 more
wiley   +1 more source

Hypnotic doses of fazamorexant induced less impairment on balance and cognition than zolpidem in healthy younger and elderly individualse

British Journal of Clinical Pharmacology, EarlyView.
Aims Fazamorexant is a dual orexin receptor antagonist being developed for the treatment of insomnia. This study aims to determine the dose‐exposure‐response relationship of single‐dose fazamorexant vs. zolpidem in young adult and elderly healthy Chinese volunteers. Methods This single‐centre, randomized, double‐blind, double‐dummy, placebo‐ and active‐
Chen Xia, Huang Xingxing, Jin Lu, Wang Ruwei   +3 more
wiley   +1 more source

Low‐dose cannabidiol increases plasma concentrations of amitriptyline: A clinical drug–drug interaction study

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Cannabidiol (CBD), the main non‐intoxicating compound from the cannabis plant, is regularly used by patients with chronic pain who also take analgesics. CBD has previously been shown to inhibit CYP‐mediated drug metabolism. This study aimed to characterize the potential pharmacokinetic interaction of CBD with amitriptyline and tramadol ...
Andriy A. Gorbenko, Titiaan E. Post, Pamela K. Strugala, Erica S. Klaassen, Linda E. Klumpers, Saco J. de Visser, Cristina Sempio, Jost Klawitter, Jules A. A. C. Heuberger, Geert J. Groeneveld   +9 more
wiley   +1 more source

Cannabinoids and drug–drug pharmacokinetic interactions: Deciphering the risks

British Journal of Clinical Pharmacology, EarlyView.
The relationship between cannabinoids and mental health has become a major focus of scientific inquiry and public discourse. Cannabinoids are diverse chemical compounds from the Cannabis species that have been explored for their therapeutic applications in treating chronic pain, psychiatric and neurological conditions, such as depression, schizophrenia,
Paraskevi Papakyriakopoulou, Georgia Valsami, Georgios Ismailos   +2 more
wiley   +1 more source

Population pharmacokinetics and dose–response relationships of mitoxantrone in children with acute myeloid leukaemia

British Journal of Clinical Pharmacology, EarlyView.
Background Information on mitoxantrone pharmacokinetics in children is lacking and reduced dosing regimens applied to infants are supported by limited scientific rationale. The current study characterized mitoxantrone pharmacokinetics in a childhood acute myeloid leukaemia patient population and provides a data‐informed assessment of dosing.
Andrew M. Brandon, Hinke Huisman‐Siebinga, Shelby Barnett, Paul Wetherell, Pamela Kearns, Brenda Gibson, Nicholas Heaney, Owen Smith, André Baruchel, Arnaud Petit, Andrew Moore, Kayode Ogungbenro, Alwin D. R. Huitema, Gareth J. Veal   +13 more
wiley   +1 more source

The Tale of the Tokugawa Artifacts: Japanese Funerary Lanterns at the Penn Museum

, 2019
That previously stood at the back of the quiet inner courtyard of the Penn Museum waited many years for its significance to be rediscovered. It is one of the Tokugawa lanterns that long illuminated the shogunate family’s grand mausoleums during the Edo ...
Nishimura, Yoko
core